October 20, 2022
October 19, 2022 | Staff Reporter – genomeweb
NEW YORK – Genetika+ has obtained CE-IVD marking for its first drug-matching test focused on major depressive disorder (MDD), the precision medicine startup said Wednesday.
The Israeli company’s product, a blood test dubbed NeuroKaire, is ordered by a physician. It predicts a patient’s likelihood of responding to various antidepressants by combining patient-reported information about symptoms with pharmacogenetics testing and functional testing based on the patient’s blood sample.
The company’s CE mark follows results from a multi-site study, in which NeuroKaire successfully predicted drug response for patients with MDD.
“This CE-IVD mark is an important milestone for Genetika+, demonstrating the accuracy and efficacy of this much needed tool in MDD and facilitating adoption of NeuroKaire in the European market,” said Talia Cohen Solal, Genetika+’s CEO and cofounder, in a statement. The company is working with physicians and hospitals to deploy NeuroKaire in clinical care.
Genetika+ was founded in 2018 to improve personalized drug prescribing for psychiatric and neurological diseases. It received €17.5 million ($17.3 million) over the summer from the European Commission’s European Innovation Council Accelerator to clinically validate and commercialize NeuroKaire.
About Genetika+
Genetika+, founded in 2018 by Talia Cohen-Solal, Ph.D., and Daphna Laifenfeld, Ph.D., is developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases. The company’s Brain-in-a-Dish technology helps physicians find the best treatment for their patients. In its first indication, depression, Genetika+ uses patented technology to rapidly test more than 70 approved antidepressants and drug combinations against an individual patient’s unique neurological biomarkers. Combined with patients’ genetic and medical history, Genetika+ can predict the optimal drug or combination therapy for each patient. This opens the door to faster treatment, fewer side effects, and lower dosing, and the elimination of arduous trial-and-error treatment protocols and needless loss of life. To learn more, follow us on LinkedIn or on Twitter @Genetikaplus.